Merck nears $1.3 bln takeover of Eyebiotech- WSJ

Investing.com-- Merck&Company Inc (NYSE: MRK) is close to entering a $1.3 billion deal to buy Eyebiotech, granting the pharmaceutical giant entry into the rapidly growing eyecare market, the Wall Street Journal reported on Tuesday.

The drugmaker is expected to pay $1.3 billion in cash for the ophthalmology firm, and could pay up to $1.7 billion in additional milestone payments, the WSJ reported, citing people with knowledge of the matter.

You May Also Be Interested In

• Papa John’s dashes near-term takeover hopes
• Macquarie buys IHS Towers' South America assets in Brazil, Colombia
• Aeternum acquires option for 51% stake in Cameroon cobalt project